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Cardiomyocyte transcriptional response to endothelin-1 <p>A microarray profiling study of rat cardiomyocytes provides insights into early and second phase transcriptional responses induced by  endothelin-1 and shows the importance of ERK1/2 signaling.</p>
Abstract
Background: Endothelin-1 stimulates Gq protein-coupled receptors to promote proliferation in
dividing cells or hypertrophy in terminally differentiated cardiomyocytes. In cardiomyocytes,
endothelin-1 rapidly (within minutes) stimulates protein kinase signaling, including extracellular-
signal regulated kinases 1/2 (ERK1/2; though not ERK5), with phenotypic/physiological changes
developing from approximately 12 h. Hypertrophy is associated with changes in mRNA/protein
expression, presumably consequent to protein kinase signaling, but the connections between early,
transient signaling events and developed hypertrophy are unknown.
Results:  Using microarrays, we defined the early transcriptional responses of neonatal rat
cardiomyocytes to endothelin-1 over 4 h, differentiating between immediate early gene (IEG) and
second phase RNAs with cycloheximide. IEGs exhibited differential temporal and transient
regulation, with expression of second phase RNAs within 1 h. Of transcripts upregulated at 30
minutes encoding established proteins, 28 were inhibited >50% by U0126 (which inhibits ERK1/2/
5 signaling), with 9 inhibited 25-50%. Expression of only four transcripts was not inhibited. At 1 h,
most RNAs (approximately 67%) were equally changed in total and polysomal RNA with
approximately 17% of transcripts increased to a greater extent in polysomes. Thus, changes in
expression of most protein-coding RN As shoul d be re fl ected in protein synthesis. However,
approximately 16% of transcripts were essentially excluded from the polysomes, including some
protein-coding mRNAs, presumably inefficiently translated.
Conclusion:  The phasic, temporal regulation of early transcriptional responses induced by
endothelin-1 in cardiomyocytes indicates that, even in terminally differentiated cells, signals are
propagated beyond the primary signaling pathways through transcriptional networks leading to
phenotypic changes (that is, hypertrophy). Furthermore, ERK1/2 signaling plays a major role in this
response.
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Background
Expression of immediate early genes (IEGs) constitutes the
first phase of gene expression in cellular responses to growth
stimuli [1]. IEGs are regulated by pre-existing transcription
factors that may be pre-bound to gene promoters. Thus, pro-
tein synthesis inhibitors (for example, cycloheximide) do not
suppress the increases in expression of IEG mRNAs. Expres-
sion of IEG RNAs could reflect changes in their rate of tran-
scription and/or mRNA stability. Intracellular signaling
pathways activated by growth stimuli regulate both processes
through phosphorylation/dephosphorylation of transcription
factors or RNA binding proteins. For example, mitogen-acti-
vated protein kinases (MAPKs) such as the extracellular sig-
nal-regulated kinases 1/2 (ERK1/2) promote
phosphorylation of several transcription factors (for example,
Elk1) to modulate their activities [2]. Signaling through
another of the MAPKs, p38-MAPK, may regulate mRNA sta-
bility through the RNA binding protein Zfp36 [3]. MicroR-
NAs and antisense RNAs also modulate mRNA levels [4,5],
and changes in expression of these regulatory RNAs may also
be expected to influence mRNA expression. Although altera-
tions in the levels of targets of micro- or antisense RNAs are
essentially secondary, transcription of their target mRNAs is
regulated by pre-existing transcription factors and does not
require protein synthesis, so they remain within the IEG
classification.
Most studies of IEGs focus on proliferating cells entering the
cell cycle, often in response to growth factors such as epider-
mal growth factor (EGF) or platelet derived-growth factor
(PDGF). The regulation of some IEGs (for example, AP1 tran-
scription factors) in these systems is well characterized.
Genome-wide IEG expression patterns are starting to be
established using microarrays but, although IEGs are known
to exhibit differences in temporal regulation [1], such studies
often aim to identify transcripts modulated at a single 'early'
time varying between 30 minutes and 4 h [6,7]. Many known
IEGs encode transcriptional regulators that presumably pro-
mote expression of downstream (second phase) genes [1].
However, the temporal distinctions between IEG and second
phase gene expression are not established and, in the absence
of these, results from a single sampling time can be difficult to
interpret. A recent microarray study demonstrated acute and
transient regulation of IEGs in proliferating cells responding
to EGF or serum [8] and highlighted negative feedback of
IEGs on gene expression, potentially accounting for the tran-
sient nature of some responses. However, feedforward tran-
scriptional signaling and the timing of second phase genes
were not defined.
Cardiomyocytes (the contractile cells of the heart) are termi-
nally differentiated. They withdraw from the cell cycle soon
after birth, and individual cardiomyocytes enlarge during the
postnatal period. Adult cardiomyocytes also hypertrophy in
order to accommodate any increase in workload (for example,
in hypertensive states). Much attention has focused on iden-
tifying stimuli that promote cardiomyocyte hypertrophy, and
in elucidating the intracellular signaling pathways they acti-
vate. Heterotrimeric Gq protein-coupled receptor agonists
(for example, endothelin (ET)-1) are particularly implicated
in the hypertrophic response [9,10]. These receptors potently
and rapidly (maximal stimulation within 5 minutes) activate
protein kinase C, Ras and ERK1/2, which are associated with
the development of cardiomyocyte hypertrophy [9,11,12]. It is
notable that peptide growth factors such as PDGF promote
hypertrophy in cardiomyocytes via protein kinase C and the
ERK1/2 cascade [13], just as ET-1 promotes proliferation of
fibroblasts and other cells that express the ETA receptor [14-
16]. It seems likely, therefore, that initial events in the hyper-
trophic response of cardiomyocytes are not dissimilar to
those of proliferating cells as they enter the cell cycle.
Although many studies have explored the intracellular signal-
ing pathways associated with cardiomyocyte hypertrophy, the
mechanisms whereby they lead to the developed phenotype
are poorly understood. Hypertrophy is characterized by mor-
phological and physiological changes (for example, increased
size and myofibrillar content) [17], presumably resulting
from changes in gene expression. These changes include an
increase in expression of established IEGs (c-jun, c-fos, c-
myc,  egr1), recapitulation of a fetal gene program, and
changes in expression of genes associated with cardiomyocyte
function [18]. Early studies indicated that IEGs are induced
rapidly in cardiomyocytes by hypertrophic stimuli [19,20],
suggesting that these promote later changes in mRNA expres-
sion associated with hypertrophic cells. However, the hyper-
trophic phenotype is more generally assumed to reflect
directly the early transcriptional changes induced by primary
signaling events [21]. An alternative explanation is that pha-
sic expression of early response genes propagates the signal,
leading to the end-stage transcriptional changes. Here, we
have explored the early transcriptional responses of cardio-
myocytes to ET-1, before major increases in protein content
and morphological changes associated with hypertrophy are
detected. We demonstrate temporal and (in many cases)
transient phases of mRNA expression consistent with the
concept that the signal is propagated through the transcrip-
tional network, leading to the end-stage changes in gene
expression associated with hypertrophy.
Results
Temporal and transient expression of RNAs induced by 
ET-1 in cardiomyocytes
Neonatal rat ventricular myocytes [22] were exposed to ET-1
(100 nM, for maximal stimulation [23]) for up to 4 h, and
RNA expression profiling was performed with Affymetrix Rat
Genome 230 2.0 arrays (>31,000 probesets covering
>28,000 well-established genes). Significant changes in
expression (false discovery rate (FDR) <0.05; 1.5-fold differ-
ence) were identified for 1,306 transcripts (30 minutes, 53
probesets; 1 h, 470 probesets; 2 h, 1,069 probesets; 4 h, 515http://genomebiology.com/2008/9/2/R32 Genome Biology 2008,     Volume 9, Issue 2, Article R32       Cullingford et al. R32.3
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probesets; Figure 1a and Additional data file 1). Increases in
expression of mRNAs of all but one (Bcr) of the 45 established
genes that were upregulated at 30 minutes were confirmed by
semi-quantitative PCR (SQPCR) or quantitative PCR (QPCR;
Additional data file 2). We previously examined the effects of
ET-1 on cardiomyocyte RNA expression at the two relatively
late time points, 2 and 4 h, using Affymetrix rat genome U34A
microarrays. These arrays are not as extensive as the 230 2.0
arrays (approximately 8,000 probesets covering approxi-
mately 7,000 established genes), so it was necessary to repeat
these times with the higher density arrays for direct compar-
ison with the early times included in this study, but we did
i d e n t i f y  7 7  p r o t e i n - c o d i n g  R N A s  w i t h  s i g n i f i c a n t  c h a n g e s
(FDR <0.05; >2-fold difference) in expression. Although the
probesets from the U34A and 230 2.0 arrays do not necessar-
ily overlap, 69 mRNAs for well-defined protein-coding genes
were identified using either array, in addition to one probeset
previously identified as Prss35 but which we have since deter-
mined to recognize the antisense strand, and three probesets
that may have 'unsafe' annotations and recognize other
potential transcripts (Additional data file 3). Linear regres-
sion analysis of the changes in expression of these RNAs for
the two array studies indicate that the data were comparable
(correlation coefficient r = 0.83; slope = 1.06 ± 0.06). Four
protein-coding RNAs we previously reported were not identi-
fied with the 230 2.0 arrays. One (Kif3c) was consistently
called 'absent'. Three (Csrp3, eIF2c2 and Prkr) showed simi-
lar changes as with the U34A arrays, but the changes were not
significant.
In our previous study [24], a large proportion of the changes
in RNA expression induced by ET-1 in cardiomyocytes at 2-4
h required ERK1/2 signaling. Of the mRNAs of the 45 estab-
lished genes upregulated by ET-1 within 30 minutes (this
study), U0126 (a selective inhibitor of ERK1/2 [25]) inhibited
the increase in expression of 28 transcripts by >50% and a
further 9 transcripts by 25-50% (Additional data file 2). Only
four upregulated transcripts were essentially unaffected by
U0126. For the remaining four transcripts, the variation in
the response to U0126 was too great for adequate assessment.
The specificity of 10 μM U0126 for MAPK kinases 1/2/5
(MKK1/2/5, the kinases immediately upstream of ERK1/2/5
and which promote their activation) is high compared with
other related kinases [26]. Since ET-1 does not promote sig-
nificant activation of ERK5 in cardiomyocytes [24], we con-
clude that ERK1/2 signaling plays a major role in regulating
the early changes in RNA expression induced in cardiomyo-
cytes by ET-1.
Unsupervised (K means) clustering identified 11 transcript
clusters (temporal clusters TC1-TC11) according to their tem-
poral regulation (four for downregulated transcripts (Figure
1b); seven for upregulated transcripts (Figure 1c)). Clusters
TC1, TC2, TC5, TC6, TC7 and TC8 represented RNAs with
changes in expression that were sustained at 4 h. However,
RNAs in clusters TC3, TC4, TC9, TC10 and TC11 were not only
temporally regulated, but the changes in expression of these
transcripts were also transient. Thus, expression of TC3/4/9/
10 RNAs had almost returned to control levels within 4 h,
whereas TC11 transcripts were elevated only at 0.5 and 1 h.
TC11 RNAs, as a whole, showed no difference in expression
between 0.5 and 1 h, although some RNAs were expressed at
substantially higher levels at either time (for example, c-fos
and egr4; Additional data file 1). Further supervised cluster-
ing of TC11 transcripts identified subclusters with signifi-
cantly greater expression at 0.5 h (TC11a) or 1 h (TC11c), or
similar expression at both times (TC11b) (Figure 1d). To avoid
incorrect annotations [27], the identities of the genes with
RNAs that were significantly changed were established by
BLAST search of probe sequences. These genes were then
classified as far as possible according to function (Figure 1e),
but many RNAs encoded hypothetical proteins or proteins of
no known function (18.6%), were derived from intronic
regions of established genes (6.5%), or could not be assigned
to any established gene (20.8%). Affymetrix expression
arrays detect numerous potential antisense transcripts [28],
and we identified 32 with altered expression in response to
ET-1. Of the genes with assigned function, a large number
were associated with transcriptional regulation or intercellu-
lar/intracellular signaling. This is consistent with the concept
that this early phase of mRNA expression is associated with
signal propagation, rather than directly establishing the
hypertrophic phenotype. The third largest group of genes
would be expected to modulate cellular metabolism, presum-
ably also an adaptation required for hypertrophy to develop.
Identification of IEGs and second phase RNAs
We used cycloheximide to dissect IEGs from second phase
transcripts and, because cycloheximide alone affects expres-
sion of a number of RNAs (data not shown), we confined our
study to RNAs whose expression was increased by ET-1.
Expression of mRNAs of established genes upregulated by
ET-1 at 30 minutes was not inhibited by 0.02 mM cyclohex-
imide (Additional data file 2). Thus, all can be considered as
IEGs (as might be expected). For RNAs upregulated at 1-2 h
(589 transcripts), the effects of cycloheximide were studied
using microarrays (Additional data file 4). Transcripts were
clustered according to time of upregulation by ET-1 and the
effect of cycloheximide (Figure 2). Sixty-six transcripts were
more potently increased by cycloheximide than by ET-1 (>2-
fold at 1 and/or 2 h). These formed 3 subclusters (CXS1, CXS2
and CXS3) with 58 transcripts (CXS1 and CXS2) demonstrat-
ing an additive/synergistic response to cycloheximide plus
ET-1 (Figure 2a, upper panels). Since these RNAs are
increased in the presence of cycloheximide, all are IEGs.
Remaining transcripts were clustered according to the degree
of inhibition of the ET-1 response by cycloheximide. Clusters
CX1a, CX1b and CX1c demonstrated <20% inhibition by
cycloheximide and were also classified as IEGs (Figure 2a,
lower panels).Genome Biology 2008, 9:R32
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Figure 1 (see legend on next page)
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Clusters CX2(a-d) were classified as probable second phase
RNAs (Figure 2b). Cycloheximide alone slightly increased the
expression of RNAs in CX2a, CX2b and CX2c, but partially
inhibited (20-80%) the increase in ET-1-induced expression
at 1 h, suggesting that full expression of these RNAs (in
response to ET-1) is mediated, at least in part, by newly syn-
thesized proteins. For CX2a and CX2b, cycloheximide further
increased RNA expression at 2 h. These may operate as IEGs
in response to cycloheximide, presumably a consequence of
signaling pathways activated by cycloheximide itself (see Dis-
cussion). CX2d RNAs were increased only at 2 h and (allow-
ing for the marginal increase by cycloheximide alone) the
increase induced by ET-1 was largely inhibited by cyclohex-
imide. CX3a and CX3b RNAs were clearly defined as part of
the second phase response, with no effect of cycloheximide
alone and >80% inhibition of the ET-1 response (Figure 2c).
CX3a therefore represents the earliest second phase RNAs we
detected, with increased expression within 1 h. However, 16
(of 27) RNAs did not correspond to any established gene,
indicating the relatively poor understanding of this phase of
the response. The numbers of IEG RNAs, probable second
phase RNAs and clear second phase RNAs that were upregu-
lated by ET-1 are summarized in Figure 2d.
Differential translation of cardiomyocyte transcripts 
regulated by ET-1
There is increasing evidence for translational regulation of
selected mRNAs, for example, in response to cellular stresses
[29] or as a consequence of Ras signaling [30,31]. To deter-
mine whether early transcriptional responses of cardiomyo-
cytes to ET-1 were subject to translational regulation, we
compared the expression profiles for total and polysome
RNAs (Figure 3a,b) from unstimulated cells and cardiomyo-
cytes exposed to ET-1 (1 h). Total microarray fluorescence val-
ues were not significantly different for any of the conditions,
but condition clustering separated polysome and total RNA
samples (Figure 3c), and principal components analysis iden-
tified three principal components for polysome or total RNA
isolated from unstimulated or ET-1-treated cardiomyocytes
(Figure 3d). Thus, the global profiles are sufficiently similar
to permit analysis as a single group, but there are significant
differences between each of the conditions.
Transcripts with significant changes in expression with ET-1
were clustered according to: increased or decreased expres-
sion in response to ET-1; relative expression in polysome or
total RNA for unstimulated cells; and relative increase or rel-
ative decrease in total and polysome RNA for ET-1-treated
cells (Figure 3e,f and Additional data file 5). Approximately
57% of upregulated RNAs (PU1, PU2 and PU3) were
increased to the same degree in total and polysome fractions,
whether expression levels were relatively higher in total RNA
than polysome RNA (PU1), similar in total or polysome RNA
(PU2), or lower in total RNA than polysome RNA (PU3) (Fig-
ure 3e, upper panels). PU4, PU5 and PU6 transcripts
(approximately 24% of upregulated RNAs) were increased to
a greater relative extent in polysome RNA (Figure 3e, centre
panels), suggesting that they may be preferentially translated.
Since PU1-PU6 represent 81% of upregulated transcripts, the
majority of upregulated, protein-coding RNAs should be effi-
ciently translated into protein. PU7 and PU8 transcripts were
upregulated by ET-1 in the total pool, but were not similarly
increased in polysomes (Figure 3e, lower panels). Indeed,
PU7 RNAs were largely excluded from the polysomes. These
clusters contained a large proportion of RNAs with no associ-
ation with any protein-coding gene, 11 of which also clustered
in CX3a and represent some of the earliest second phase
response RNAs (Figure 2c). Approximately 85% of downreg-
ulated transcripts (PD1 and PD2) were decreased to a similar
degree in total and polysome RNA (Figure 3f). However,
small clusters of transcripts were identified that had a sub-
stantial decrease in expression in total RNA and a small
decrease in polysome RNA and/or were essentially excluded
from polysomes in control or ET-1-treated cells (PD3 and
PD4). Of the 17 transcripts in these clusters, only two had pro-
tein-coding identity. In summary, although there is evidence
for preferential recruitment of R N A s  t o  o r  a w a y  f r o m  t h e
translational apparatus, for >80% of transcripts with signifi-
cant changes in expression induced by ET-1, we would expect
protein translation to reflect changes in mRNA expression.
This has been confirmed by western blotting for upregulated
IEGs in PU2 (for example, JunB, Figure 4a), PU3 (for exam-
ple, Egr1, Figure 4b), PU4 (for example, interleukin (IL)-6,
Figure 4c), PU5 (for example, c-Fos, Figure 4d) and PU6 (for
example, Atf3, Figure 4e).
Temporal changes in RNA expression induced by ET-1 in cardiomyocytes Figure 1 (see previous page)
Temporal changes in RNA expression induced by ET-1 in cardiomyocytes. (a) The 1,494 probesets identified as significantly (FDR <0.05; 1.5-fold 
difference) up- or downregulated in response to ET-1 at 0.5, 1, 2 or 4 h were clustered using a Pearson complete correlation and are presented as a 
heatmap of the mean change at each time (Log10 scale: cyan = zero, black = 1, red = 6). (b,c) K means clustering generated four groups (TC1-TC4) of 
downregulated transcripts (b), and seven groups (TC5-TC11) of upregulated transcripts (c). The numbers of different transcripts for each group are 
shown in parentheses. (d) Supervised clustering of TC11 identified three subclusters (TC11a, TC11b and TC11c; numbers of transcripts in each group in 
parentheses) demonstrating differential temporal and transient expression before 2 h. (Note that three genes exhibited apparent increases in excess of 20-
fold (Egr4, 50-fold; c-Fos, 28-fold; FosB, 306-fold) and were excluded from this clustering because of the excessive bias introduced.) Statistical significance 
(repeated measures one-way ANOVA with Tukey post-test) p < 0.05 for all times versus all other times except for the following (not significantly 
different): TC2, 0.5 versus 1 h; TC3, 0 versus 4 h and 0.5 versus 2 h; TC4, 0.5 versus 4 h; TC5, 1 versus 2 or 4 h, 2 versus 4 h; TC6, 0 versus 0.5 or 1 h; 
TC7, 0 versus 0.5, 2 versus 4 h; TC8, 0 versus 0.5 or 1 h, 0.5 versus 1 h; TC9, 0 versus 0.5 or 4 h, 0.5 versus 4 h, 1 versus 2 h; TC10, 0 versus 0.5 h, 1 
versus 4 h; TC11, 0 versus 2 or 4 h, 0.5 versus 1 h, 2 versus 4 h. (b-d) Results are means ± SEM for the numbers of transcripts given in parentheses. (e) 
Classification of genes regulated by ET-1 according to known or probable function (see Additional data file 1 for details).Genome Biology 2008, 9:R32
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Figure 2 (see legend on next page)
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Validation of microarray data
Our microarray data were validated using SQPCR or QPCR
for mRNAs of the 45 established genes upregulated at 30
minutes, and QPCR for 22 genes selected from the cyclohex-
imide and polysome clusters. Qualitatively, the differences in
expression of all but one of the 30 minute transcripts at 30
minutes (Bcr) and one identified at 1-2 h (Hipk3) were con-
firmed (Additional data file 6). This is within our tolerance of
FDR <0.05. The apparent fold stimulation observed for
arrays versus QPCR often differed but transcripts selected for
cluster validation (other than Hipk3) showed a high degree of
linear correlation across 11 experimental conditions, suggest-
ing that the differences were i n n a t e  t o  t h e  e x p e r i m e n t a l
approaches. Our validation was generally based on amplifica-
tion across introns of established genes rather than confined
to the probe sequences, and at least some differences (appar-
ent degree of stimulation; failure to validate Bcr and Hipk3)
may be explained by alternative splicing.
Discussion
The concept of IEGs versus second phase and subsequent
phases of gene expression is established in prokaryotic sys-
tems and in eukaryotic proliferating cells [1]. However, in
more differentiated cell types, this concept has been
neglected and it seems to be more generally assumed that
classic intracellular signaling events (for example, protein
kinase cascades) lead directly to changes in gene expression
associated with the end-stage phenotype, such as developed
hypertrophy in cardiomyocytes [21]. Even in proliferating
cells, knowledge and understanding of IEGs versus second
phase genes is rather limited. Here, we have demonstrated
that, in cardiomyocytes, ET-1 promotes multiple phases of
RNA expression within the first 4 h of stimulation, before
major morphological changes or accumulation of total pro-
tein are observed (Figure 1). We expected to see the temporal
and transient changes in RNA expression over the period
studied, but the patterns were perhaps more complex than
anticipated. For example, expression of some IEGs was max-
imal within 30 minutes (cluster TC11a) whereas others were
delayed, with maximal expression at 1 h (cluster TC11c). This
contrasts with studies of pancreatic cells exposed to glucose
and 8-(4-chloro-)phenylthio-cAMP (CPTcAMP) in which
IEGs are expressed as long as the stimulus is present, and in
which IEGs were dissected from second phase transcripts at 4
h [7]. In cardiomyocytes, expression of IEGs had largely
ceased by 4 h. The differences presumably reflect persistent
activation of intracellular signaling pathways by CPTcAMP
versus activation of endogenous second messengers by
endogenous receptors, with transient activation of signaling
pathways [10].
Our study was based on stimulation of neonatal rat ventricu-
lar myocytes by ET-1. U0126 (an inhibitor or ERK1/2 signal-
ing) attenuated the changes in expression for the majority of
the RNAs upregulated in cardiomyocytes by ET-1 at either 30
minutes (Additional data file 2) or 2 h [24], so many of the
same transcriptional changes sho u l d  b e  d e t e c t e d  i n  o t h e r
cells responding to agonists that potently activate the ERK1/
2 cascade. Indeed, changes in RNA expression reported for
other such systems (for example, fibroblasts exposed to
PDGF [32] or HeLa cells exposed to EGF [8]) overlap sub-
stantially with those identified here. Of the genes with known
or probable function, very few were associated with end-stage
cardiac hypertrophy [17]. Even in terms of functional groups,
these early changes differ markedly from later phases of
hypertrophy or heart failure in which genes associated with
energy metabolism, extracellular matrix and/or contractility
p r e d o m i n a t e  [ 3 3 - 3 6 ] .  I n s t e a d ,  m a n y  w e r e  a s s o c i a t e d  w i t h
gene or protein expression, or with signaling. These presum-
ably are required for signal propagation towards the end-
stage phenotype, and would modulate cardiomyocyte respon-
siveness to the immediate environment in the intervening
period.
Cycloheximide is classically used to define IEGs. However, it
also stimulates protein kinase signaling (for example, c-Jun
N-terminal kinases (JNKs) and p38-MAPKs [37,38]) and
independently promotes expression of certain genes. Consist-
ent with this, we detected significant changes in expression
(FDR <0.05; >1.5-fold difference relative to controls) of 1,046
probesets in cardiomyocytes exposed to cycloheximide alone
for 70 or 130 minutes (to include the 10 minute pre-incuba-
tion period used in association with ET-1), many of which
were not changed in response to ET-1 (data not shown). These
would seem to be potential IEGs (that is, genes that may be
regulated as IEGs in response to other stimuli). For example,
cycloheximide increased expression of Gdf15 (3.44 ± 0.36-
fold at 70 minutes; 5.69 ± 0.62-fold at 130 minutes), a gene
whose expression is increased in cardiomyocytes by H2O2
Identification of immediate early and second phase RNAs with increased expression in response to ET-1 Figure 2 (see previous page)
Identification of immediate early and second phase RNAs with increased expression in response to ET-1. Cardiomyocytes were unstimulated (Control), 
exposed to cycloheximide (CX) alone, or to ET-1 (ET) in the absence or presence of cycloheximide for 1 h (solid bars) or 2 h (open bars). (a) RNAs in 
CXS1, CXS2 and CXS3 (whose induction by ET-1 was further increased by cycloheximide), and CX1a, CX1b and CX1c (whose induction was not 
inhibited by cycloheximide) were classified as immediate early gene RNAs. (b) CX2a, CX2b, CX2c and CX2d RNAs showed partial inhibition of the 
response to ET-1 at 1 h by cycloheximide and are probably second phase RNAs. (c) CX3a and CX3b RNAs were clearly second phase RNAs with >80% 
inhibition of the response to ET-1 by cycloheximide. The numbers of transcripts in each cluster are shown in parentheses. Statistical significance (repeated 
measures one-way ANOVA with Tukey post-test) p < 0.05 for Control versus ET-1 (2 h; all clusters), Control versus ET-1 (1 h; all clusters except CXS3, 
CX1c, CX2d and CX3b), Control versus CX (1 or 2 h; all clusters in (a)), ET-1 (2 h) versus CX+ET-1 (2 h) (all clusters except CX2a/b), ET-1 (1 h) versus 
CX+ET-1 (1 h) (all clusters except CX1b/c, CX2d and CX3b). (a-c) Results are means ± SEM for three independent sets of samples. (d) Numbers of IEG 
versus second phase genes upregulated in cardiomyocytes in response to ET-1 over the first 2 h.Genome Biology 2008, 9:R32
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Figure 3 (see legend on next page)
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[39] but not ET-1, and which may play a role during the devel-
opment of cardiac pathologies [40,41]. Nevertheless, by con-
f i n i n g  o u r  a n a l y s i s  h e r e  t o  o n l y  R N A s  w i t h  i n c r e a s e d
expression in response to ET-1, we could identify IEGs, and
inhibition of responses by cycloheximide clearly defined
downstream gene expression. We expected to find a number
of second phase transcripts after 2 h of stimulation with ET-
1, but there were approximately twice as many probable or
clear second phase transcripts as IEGs at this time (Figure 2b-
d). We also identified a small group of second phase RNAs
with increased expression at 1 h, at least some of which are
protein-coding (CX3a; Figure 2c and Additional data file 4).
Thus, the second phase of RNA expression is induced rapidly
in cardiomyocytes and it cannot be assumed that all tran-
scripts that are upregulated at 1-2 h are IEGs, nor can it be
assumed that RNAs that are upregulated from 2 h are neces-
sarily part of the second phase response.
Of the IEGs, some (for example, CX1a RNAs) were upregu-
lated by ET-1 at 1 h with reduced expression at 2 h, but were
superinduced by cycloheximide at 2 h. For these, synthesis of
a negative regulator could be required to suppress the
response. One such protein is likely to be Atf3, a negative reg-
ulator of gene expression in other systems [42] whose mRNA
and protein is increased within 30 minutes (Additional data
file 2; Figure 4e). The delayed expression of some IEGs at 2 h
(Figure 2a, CX1c and CXS3) relative to others induced at 0.5-
1 h (Additional data file 2; Figure 2a, CXS1 and CX1a) may
relate to differential effects on mRNA stability and transcrip-
tion. Although unexplored in cardiomyocytes, a rapid
increase in mRNA stabilization increases RNA expression in
other systems [43]. Alternatively (or additionally), temporal
differences in RNA expression could reflect temporal differ-
ences in activation of intracellular signaling pathways that
regulate transcription factor activity (for example, stimula-
tion of JNKs by ET-1 in cardiomyocytes is delayed relative to
ERK1/2 [44,45]).
Studies of global transcriptional profiles raise the question of
whether the mRNAs are translated into protein. Although
proteomics studies can address this, methodologies using
two-dimensional gel electrophoresis to separate proteins
have restrictions with respect to resolution and/or detection
levels, whereas analysis of the full proteome by mass spec-
trometry is highly complex. Furthermore, such studies exam-
ine the total level of proteins, favoring those that are more
abundant. In cardiomyocytes, we have found it difficult to
identify, for example, transcription factors that are expressed
at low abundance relative to the myofibrillar or cytoskeletal
apparatus using this methodology. In a different approach,
other studies have demonstrated selective recruitment of
transcripts to polysomes and suggested that translational reg-
Analysis of cardiomyocyte polysome RNA Figure 3 (see previous page)
Analysis of cardiomyocyte polysome RNA. Cardiomyocyte extracts from unstimulated cells (Control) or cells exposed to ET-1 (ET) for 1 h were 
subjected to sucrose density centrifugation. Fraction 1 is the top and fraction 12 the bottom of the gradient. (a) A254 profiles for sucrose density gradients. 
(b) Agarose gel electrophoresis with ethidium bromide staining of RNA isolated from each fraction highlights 28S, 18S and 5S ribosomal RNA. Fractions 
6-11 were pooled for preparation of polysomal RNA for expression profiling. (c) All probesets were used for condition clustering (Pearson complete 
correlation) of polysome and total RNA prepared from individual sets of samples, and a heatmap of the mean normalized expression for each sample is 
shown (Log10 scale: cyan = zero, black = 1, red = 6). (d) Principal components analysis identified three components. (e,f) RNAs identified as being 
significantly changed in the total pool in response to ET-1 at 1 h were clustered according to the profiles in total and polysome RNA giving eight groups 
with increased expression (e) and four groups with decreased expression (f). Results are means ± SEM for four independent sets of samples. Statistical 
significance (repeated measures one-way ANOVA with Tukey post-test) p < 0.05 for Control total versus Control polysome (all clusters except PU2, PU5 
and PU8), ET-1 total versus ET-1 polysome (all clusters except PU7, PU8, PD3 and PD4).
Upregulation of JunB, Egr1, IL-6, c-Fos and Atf3 in cardiomyocytes  exposed to ET-1 Figure 4
Upregulation of JunB, Egr1, IL-6, c-Fos and Atf3 in cardiomyocytes 
exposed to ET-1. (a,b,d,e) Cardiomyocytes were exposed to ET-1 for 
the times indicated. Nuclear extracts were analyzed by western blotting 
using antibodies to JunB (a), Egr1 (b), c-Fos (d) or Atf3 (e). (c) 
Cardiomyocytes were unstimulated (Control) or exposed to ET-1 and the 
tissue culture medium changed and collected at 1 h (0-1 h secretions) then 
at 2 h (1-2 h secretions). IL-6 in the media was detected by western 
blotting using slot blotting to transfer proteins to the nitrocellulose. 
Experiments were repeated with similar results.
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ulation is an important component of responses to cellular
stress or, for example, Ras signaling [29-31]. We detected dif-
ferential recruitment of transcripts to polysomes in cardio-
myocytes, both in the unstimulated state and following
exposure to ET-1 (Figure 3), consistent with studies in other
systems [29-31]. However, 67% of the transcripts that were
changed in cardiomyocytes in response to ET-1 exhibited sim-
ilar changes in expression in total RNA and polysome RNA,
with a further 17% of upregulated transcripts being increased
to a greater extent in polysome RNA than in total RNA. Thus,
for the majority of transcripts, we expect protein translation
to reflect the changes in mRNA abundance. This is the case
for the mRNAs/proteins we have studied previously (for
example, c-Jun [46], connective tissue growth factor [47])
and those we studied as a consequence of our microarray
data, including JunB, Egr1, IL-6, c-Fos and Atf3 (Figure 4).
A principal difference between our study of polysomal RNAs
and those of others is that we studied the early phases of a
growth response, confining the analysis to RNAs with altered
expression in the global RNA pool. Others have examined
polysomal RNA specifically in the context of cellular stresses
or sustained activation of signaling pathways and did not con-
fine the study only to transcripts that were altered in the glo-
bal pool [29-31]. However, even in our study, up to 18% of
RNAs were preferentially excluded from polysomes (PU7,
PU8, PD3 and PD4). These clusters contained a high propor-
t i o n  o f  R N A s  t h a t  w e r e  n o t  a s s o c i a t e d  w i t h  a n y  k n o w n
protein-coding gene. Although such genes may still be identi-
fied for these transcripts, 31 of the total 72 different tran-
scripts corresponded to intronic regions of protein-coding
genes. This contrasts with only 7 of 332 transcripts in all other
clusters. It remains to be determined whether they are simply
by-products generated from splicing of the primary tran-
scripts or if they are themselves functional transcripts. More
generally, particularly as we failed to assign any clear function
to almost 50% of the RNAs associated with the early response
to ET-1 (allowing for transcripts corresponding to hypotheti-
cal proteins, transcripts outside any established or predicted
gene, transcripts derived from intronic regions and antisense
sequences), much remains to be learnt about how the early
transcriptional response of cardiomyocytes is integrated and
leads to changes in cell function.
Conclusion
Although it is assumed that protein kinase/phosphatase sign-
aling regulates gene expression in cardiomyocytes and these
events are associated with phenotypic changes, the intercon-
nections between the rapid and transient regulation of pro-
tein kinases/phosphatases and (with respect to ET-1)
hypertrophy have not been established. We have demon-
strated that, even though cardiomyocytes are terminally dif-
ferentiated, a stimulus such as ET-1 still promotes multiple
phases of RNA expression, prior to those associated with
developed hypertrophy, but which presumably are required
for the growth response to develop. Thus, the signal is propa-
gated beyond the primary signaling pathways through tran-
scriptional networks. In cardiomyocytes exposed to ET-1, a
large pool of mRNAs were regulated as IEGs over the first 2 h
of stimulation, with changes in expression of second phase
RNAs from within the first hour. Since ET-1 potently activates
ERK1/2 signaling and this pathway plays a major role in reg-
ulating RNA expression in this context, we suggest that many
of the same genes will be regulated as IEGs or second phase
genes in other systems that signal predominantly through the
ERK1/2 cascade. Finally, our data on RNA recruitment to car-
diomyocyte polysomes indicate that, for most transcripts,
translation of IEGs into protein should reflect the changes in
mRNA expression. Nevertheless, some transcripts are prefer-
entially excluded from the polysomes and are presumably
subject to translational regulation. Overall, our study illus-
trates the complexities of the early transcriptional response to
a single stimulus and contributes to our understanding of the
mechanisms associated with signal propagation towards the
ultimate and distant phenotypic response.
Materials and methods
Cardiomyocyte cultures
Ventricular myocytes from neonatal rats are terminally dif-
ferentiated [22], but can be maintained in primary culture as
a confluent monolayer of spontaneously beating cells. Cardi-
omyocytes were dissociated from neonatal (1-3 day) Sprague-
Dawley rat hearts (at least 4 litters per preparation) and cul-
tured at confluence (4 × 106 cells per 60 mm Primaria dish) as
described previously [39]. Myocytes were plated in 15% (v/v)
fetal calf serum (18 h) and then serum-starved (24 h) before
being left unstimulated, exposed to 100 nM ET-1 (Bachem
(UK) Ltd., St Helens, UK) or 20 μM cycloheximide, or
exposed to ET-1 following pre-treatment (10 minutes) with
20 μM cycloheximide.
Preparation of cardiomyocyte polysomes
Sucrose density gradients were prepared by layering 900 μl
each of 1.6 M, 1.4 M, 1.2 M, 1.0 M, and 0.8 M sucrose in buffer
A (50 mM Tris-HCl pH 7.4, 100 mM KCl, 2 mM MgCl2, 0.1
mg/ml cycloheximide) in 5 ml ultracentrifuge tubes. Gradi-
ents were equilibrated overnight (4°C). Cardiomyocytes (16 ×
106 cells per sample) were treated with cycloheximide before
harvesting (0.1 mg/ml, 5 minutes), then washed 3 times in
ice-cold phosphate-buffered saline containing 0.1 mg/ml
cycloheximide. Cells were scraped into 0.3 ml buffer A con-
taining 0.5% (v/v) Triton X100, 0.5% (v/v) Nonidet P40, 0.25
mM dithiothreitol, 1 mg/ml heparin, 40 U/ml RNaseOut
(Invitrogen Ltd., Paisley, UK), 0.3 mM
phenylmethylsulphonyl fluoride, 0.2 mM leupeptin, 0.002
mM microcystin LR and 0.01 mM trans-epoxy-succinyl-L-
leucylamido-(4-guanidino)-butane, and incubated on ice (10
minutes). Extracts were centrifuged (4°C, 20 minutes,
20,000 × g) and the supernatants layered onto the sucrose
density gradients. Samples were centrifuged (Sorvall M120SEhttp://genomebiology.com/2008/9/2/R32 Genome Biology 2008,     Volume 9, Issue 2, Article R32       Cullingford et al. R32.11
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ultracentrifuge), 4°C, 2 h, 105,000 × g). Fractions (12 in total)
were collected by upward displacement whilst monitoring
absorbance at 254 nm.
RNA preparation and microarray hybridization
Total RNA was prepared (4 × 106 cells per sample) as previ-
ously described [48]. Polysome RNA was extracted from frac-
tions 6-11 using RNA Bee (according to the manufacturer's
instructions, AMS Biotechnology (Europe) Ltd., Abingdon,
UK) and resuspended in 15 μl water. Pooled fractions were
incubated with 90 μl 3 M sodium acetate and 180 μl ethanol
(5 minutes, 4°C), then centrifuged (4°C, 15 minutes, 20,000
× g). The pellets were washed in 80% (v/v) ethanol and resus-
pended in 15 μl water. RNA concentrations were determined
at A260. A260/A280 ratios were 1.9-2.0. For total or polysome
RNA, each sample was generated by combining equal
amounts of RNA from three independent preparations of
myocytes. Separate samples were generated for hybridization
to individual microarrays: n = 3 (prepared from 9 myocyte
preparations) for the ET-1 time course (0, 0.5, 1, 2 and 4 h); n
= 3 (prepared from 9 myocyte preparations) for control,
cycloheximide, ET-1 or cycloheximide/ET-1 (1 and 2 h); n = 4
(prepared from 12 myocyte preparations) for total versus
polysome RNA for control or ET-1 (1 h). By using all data for
each individual time point, we obtained n = 3 for ET-1 at 0.5
or 4 h, n = 8 for ET-1 at 1 h and n = 6 for ET-1 at 2 h. Unstim-
ulated controls were prepared and hybridized simultaneously
with each set of samples. Samples were further purified and
concentrated using the RNeasy Minielute Cleanup kit (Qia-
gen Ltd., Crawley, UK). cDNA and cRNA were synthesized as
previously described [48]. Fragmentation of antisense cRNA
and hybridization to Affymetrix Rat Genome 230 2.0 arrays
were performed at the CSC/MRC Microarray Centre accord-
ing to their protocol [49]. Data were exported to ArrayEx-
press (E-MIMR-3, E-MIMR-681).
Data analysis
Preliminary analysis of hybridization data used Affymetrix
GeneChip Operating System, GCOS. The data were imported
into GeneSpring GX 7.3.1 (Agilent Technologies UK Ltd.,
Stockport, UK) as tab-delimited text files. Log10 values were
used for subsequent analysis with values set to a minimum of
0.01. For each dataset, the data were normalized per array (to
the 50th percentile) and then per gene. For studies of the tem-
poral changes in RNA expression induced by ET-1 and the
effects of cycloheximide, normalization per gene was to the
corresponding controls (prepared and hybridized simultane-
ously). For the study of expression in total and polysome
RNA, data were normalized to the median for each gene for all
samples in the experiment (that is, n = 16). The error model
was based on deviation from 1 (assumes that most transcripts
in the array will not change). A confidence filter was applied
and genes were selected if present or marginal in all controls
or all of any given time. One-way non-parametric t-tests were
performed for each transcript for each time relative to the
appropriate controls. The FDR was set to <0.05 and multiple
testing correction performed using the Benjamini and Hoch-
berg FDR algorithm. Transcripts were filtered on the basis of
>1.5-fold difference. All gene identities were confirmed by
BLAST search of the probeset sequences using the Entrez
nucleotide database [50]. Further BLAST searches for unas-
signed sequences were performed against the rat genome [51]
and, since the rat genome is still less well annotated, the
mouse genome [52] (cross-species megaBLAST). Annota-
tions were correct as of August 2007. Genes were classified as
far as possible using Gene Ontology classifications associated
with rat, mouse and human orthologues [53], taking into
account both probable 'function' and 'process'. For genes with
conflicting potential functions, further searches were per-
formed using PubMed to ascertain probable biochemical
function. Genes were grouped according to their biochemical
function in the cell.
For the cycloheximide study, data (n = 3) were obtained for
cardiomyocytes treated with cycloheximide (70 or 130 min-
utes), ET-1 (60 or 120 minutes) or cycloheximide and ET-1
(10 minutes pretreatment with cycloheximide before adding
ET-1 for 60 or 120 minutes). Genes were selected for analysis
if significantly upregulated in response to ET-1 at 1 or 2 h
according to the time course study. Normalized data were
exported for supervised clustering using Microsoft Excel. For
the study of polysome RNAs, data were obtained for total
RNA or polysome RNA from unstimulated cardiomyocytes or
cardiomyocytes exposed to ET-1 for 1 h (n = 4, total and poly-
some RNAs from the same cardiomyocyte preparations).
Principal components analysis and condition clustering were
performed using GeneSpring GX 7.3.1. Genes were selected
for analysis if significantly upregulated or downregulated in
response to ET-1 at 1 h according to the time course study.
Normalized data were exported for supervised clustering with
Microsoft Excel.
K means clustering was performed using GeneSpring GX
7.3.1 using a Pearson correlation allowing up to 100 iterations
with testing of 5 additional random clusters. For the time
course data (Additional data file 1), 11 clusters proved to be
optimum, with clustering converging after 19 iterations. To
confirm statistical significance for the cluster sets, normal-
ized values were exported and analyzed by GraphPad Prism 4
(GraphPad Software Inc., San Diego, CA, USA) using
repeated measures one-way ANOVA with Tukey post-test.
Linear regression analysis was performed using GraphPad
Prism 4.
Reverse transcription-PCR
Primers for SQPCR or QPCR were designed for established
genes using published rat sequences (Additional data file 7).
Where possible, these were designed across an intron. cDNA
was prepared by reverse transcription of RNA samples and
SQPCR was performed essentially as described [48] using
(for all primer pairs) an amplification cycle of 95°C for 30 s,
59°C for 30 s and 72°C for 30 s. The optimum cycle numberGenome Biology 2008, 9:R32
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determined for each amplicon. Amplified products were visu-
alized on 2% (w/v) agarose gels with Sybr-Safe (Invitrogen)
staining and the bands were recorded under UV illumination.
The expression of the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) was monitored in paral-
lel. Products were identified according to size. Bands were
quantified by scanning densitometry (ImageMaster 1D, GE
Healthcare, Bio-Sciences, Chalfont St Giles, UK) and values
were expressed relative to that of Gapdh amplified from the
same cDNA sample. QPCR was performed using a 7500 Real-
Time PCR System (Applied Biosystems, Warrington, UK). A
master-mix containing (per reaction) 12.5 μl Sybr-Green
Jump Start Taq Readymix (Sigma-Aldrich Co. Ltd., Gilling-
ham, UK) and 5 μl oligonucleotides (5 pmol each of forward
and reverse primers) was aliquoted into Optical 96-well reac-
tion-plates (Applied Biosystems), and cDNA template added
(7.5 μl, 1/15 dilution in water). PCR conditions for all primer
pairs were 50°C for 2 minutes, 95°C for 10 minutes, followed
by 40 cycles of 95°C for 15 s and 59°C for 60 s. Following
QPCR, dissociation curve analysis was performed to check for
aberrant amplification products. QPCR analysis of Gapdh
was performed in each 96-well plate as an endogenous con-
trol and the relative quantification protocol was used.
Western blotting
Western blotting of cardiomyocyte nuclear extracts was per-
formed essentially as described [54] using primary antibodies
to JunB (Santa Cruz Biotechnology Inc., distributed by
AutogenBioclear, Calne, UK, JunB(N-17)X sc-46X, 1/2,000
dilution), Egr1 (Santa Cruz Biotechnology Inc., Egr1(C-19) sc-
189, 1/500 dilution), c-Fos (Santa Cruz Biotechnology Inc., c-
Fos (4)X, sc-52X, 1/10,000 dilution) or ATF3 (Santa Cruz
Biotechnology Inc., ATF2(C19) sc-188, 1/500 dilution). For
IL-6, tissue culture media were collected from unstimulated
cardiomyocytes or from cardiomyocytes exposed to ET-1 over
0-1 h, the medium was replaced and then collected again at 2
h. Proteins in 300 μl were transferred to nitrocellulose by slot
blotting. Blots were probed with primary antibodies to IL-6
(Santa Cruz Biotechnology Inc., IL-6(R-19) sc-1266, 1/2,000
dilution) and developed as described in [54].
Abbreviations
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Additional data files
The following additional data are available. Additional data
file 1 is a spreadsheet listing the variably expressed genes clas-
sified according to function and clustered according to time.
Additional data file 2 contains tables listing SQPCR and
QPCR validation data for the RNAs that were upregulated by
ET-1 at 30 minutes, and the effects of (a) cycloheximide or
(b) U0126. Additional data file 3 is a spreadsheet comparing
the data we previously reported for the changes in RNA
expression induced by ET-1 at 2 or 4 h [24] with the data gen-
erated in this study. Additional data file 4 is a spreadsheet
listing the RNAs that were upregulated by ET-1 at 1 or 2 h,
clustered according to the effects of cycloheximide. Addi-
tional data file 5 is a spreadsheet listing the RNAs that were
variably expressed at 1 h, clustered according to their distri-
bution in polysome or total RNA pools. Additional data file 6
is a table of QPCR data for validation of cycloheximide and
polysome clusters. Additional data file 7 is a table with details
of the primers used for SQPCR or QPCR.
Additional data file 1 Variably expressed genes classified according to function and clus- tered according to time Variably expressed genes classified according to function and clus- tered according to time. Click here for file Additional data file 2 SQPCR and QPCR validation data for the RNAs that were upregu- lated by ET-1 at 30 minutes, and the effects of cycloheximide or  U0126 SQPCR and QPCR validation data for the RNAs that were upregu- lated by ET-1 at 30 minutes, and the effects of (a) cycloheximide or  (b) U0126. Click here for file Additional data file 3 Comparison of the data we previously reported for the changes in  RNA expression induced by ET-1 at 2 or 4 h with the data generated  in this study Data previously reported for the changes in RNA expression  induced by ET-1 at 2 or 4 h are from [24]. Click here for file Additional data file 4 RNAs that were upregulated by ET-1 at 1 or 2 h, clustered according  to the effects of cycloheximide RNAs that were upregulated by ET-1 at 1 or 2 h, clustered according  to the effects of cycloheximide. Click here for file Additional data file 5 RNAs that were variably expressed at 1 h, clustered according to  their distribution in polysome or total RNA pools RNAs that were variably expressed at 1 h, clustered according to  their distribution in polysome or total RNA pools. Click here for file Additional data file 6 QPCR data for validation of cycloheximide and polysome clusters QPCR data for validation of cycloheximide and polysome clusters. Click here for file Additional data file 7 Primers used for SQPCR or QPCR Primers used for SQPCR or QPCR. Click here for file
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